Tectonic Therapeutic, Inc. (TECX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tectonic Therapeutic, Inc. (TECX) closed at USD 20.96 on 2026-10-14, a change of +17.2 % over the past year, with a market capitalization of USD 416.4M.

Tectonic Therapeutic, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tectonic Therapeutic, Inc. key figures

Previous close

USD 20.96 (2026-10-14)

1-year change

+17.2 %

Market cap

USD 416.4M

Enterprise value

USD 193.73M

P/E ratio (trailing)

-4.67

P/E ratio (forward)

-4.48

EPS (trailing)

-4.56

EPS (forward)

-4.76

PEG ratio

n/a

Price to book

1.83

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.84

Employees

60

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tectonic Therapeutic, Inc. and compare it with other stocks.